151 related articles for article (PubMed ID: 27162541)
1. Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.
Ito T; Kohashi K; Yamada Y; Iwasaki T; Maekawa A; Kuda M; Hoshina D; Abe R; Furue M; Oda Y
J Cancer; 2016; 7(7):823-30. PubMed ID: 27162541
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma.
Ito T; Kohashi K; Yamada Y; Maekawa A; Kuda M; Furue M; Oda Y
Histopathology; 2016 Jul; 69(1):63-71. PubMed ID: 26619071
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
4. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
[TBL] [Abstract][Full Text] [Related]
5. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
7. Expression of Forkhead Box M1 (FOXM1) and anticancer effects of FOXM1 inhibition in epithelial sarcoma.
Shibui Y; Kohashi K; Hino Y; Tamaki A; Kinoshita I; Yamamoto H; Nakashima Y; Tajiri T; Oda Y
Lab Invest; 2024 Jun; ():102093. PubMed ID: 38857782
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
[TBL] [Abstract][Full Text] [Related]
9. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma.
Egawa M; Yoshida Y; Ogura S; Kurahashi T; Kizu T; Furuta K; Kamada Y; Chatani N; Hamano M; Kiso S; Hikita H; Tatsumi T; Eguchi H; Nagano H; Doki Y; Mori M; Takehara T
Hepatol Res; 2017 Oct; 47(11):1196-1205. PubMed ID: 28002884
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. FOXM1: a new therapeutic target of extramammary Paget disease.
Ito T; Tanaka Y; Kaku-Ito Y; Oda Y; Nakahara T
Sci Rep; 2024 Feb; 14(1):4048. PubMed ID: 38374400
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia.
Wang JY; Jia XH; Xing HY; Li YJ; Fan WW; Li N; Xie SY
Mol Med Rep; 2015 Jul; 12(1):1457-64. PubMed ID: 25760224
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.
Ahn H; Sim J; Abdul R; Chung MS; Paik SS; Oh YH; Park CK; Jang K
J Korean Med Sci; 2015 Apr; 30(4):390-7. PubMed ID: 25829806
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer.
Kong FF; Qu ZQ; Yuan HH; Wang JY; Zhao M; Guo YH; Shi J; Gong XD; Zhu YL; Liu F; Zhang WY; Jiang B
Oncol Rep; 2014 Jun; 31(6):2660-8. PubMed ID: 24715097
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
[TBL] [Abstract][Full Text] [Related]
19. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of FOXM1 in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.
Harada K; Ferdous T; Minami H; Mishima K
Mol Clin Oncol; 2019 Jan; 10(1):29-36. PubMed ID: 30655974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
